A compound of Formula, and pharmaceutically acceptable salts, N-oxides, or solvates thereof, wherein X is NH or S; R 1a and R 1b are independently selected from the group consisting of H, 3 H, halo, -CH 3, -CH 2 CH 3, -CF 3, -OCH 3, -OCF 3, and -CN; R 2 is selected from the group consisting of: halo; C 1-5a lkyl; C 1-5 alkenyl; C 1-5 haloalkyl; C 1-5 alkoxy; C 1-5 haloalkoxy; -(C=O)H; -CH 2 C(=O)NH(CH 3); -CO 2 C 1-5 alkyl; -CN; - CH 2 CN; -CH(CH 3)CN; -C(CH 3) 2 CN; -OCH 2 CN; phenyl; phenyl substituted with halo, C 1-5 alkoxy, or -CN; -O-phenyl; benzyl; benzyl substituted with halo; -O-benzyl; C 3-6 cycloalkyl; -OC 3-6 cycloalkyl; -O-thiazolyl; pyrimidinyl; pyridyl; pyridyl substituted with halo, C 1-5 alkoxy, or C 1-5 haloalkyl; -NH-CH 2 -furyl; -C 3-6 cycloalkyl substituted with CN; -CH 2 morpholine; CH 2 -N-methylpiperazine; pyrazolyl; pyrazole substituted with -CH 2 CH 2 OCH 3, or C 1-5 alkyl; isoxazole substituted with two C 1-5 alkyl; -O-CH 2 -C 3-6 cycloalkyl optionally substituted with halo; piperazine substituted with -CO 2 tBu; - O-azetidine substituted with -CO 2 tBu; and 8-quinolyl; R 3 is selected from the group consisting of: H; halo; C 1-5 alkyl; C 1-5 haloalkyl; C 1-5 alkoxy; C 1-5 haloalkoxy; -CN; -CH 2 CN; CO 2 C 1-5 alkyl; -N(CH 3) 2; -(C=O)N(C 1-5 alkyl) 2; - (C=O)NH-cyclopropyl; -(C=O)NH-phenyl; -(C=O)morpholine; -O-cyclopropyl; -O-CH 2 -cyclopropyl substituted with halo; -O-azetidinyl substituted with -CO 2 tBu; CH 2 -pyrrolidine; piperidine; piperidine substituted with -OCH 3; -CH 2 -piperidine; -CH 2 -piperidine substituted with -OH and halo; -CH 2 -morpholine; CH 2 -morpholine substituted with one or two C 1-5 alkyl or C 1-5 haloalkyl; CH 2 -thiomorpholine; CH 2 -piperazine substituted with -CO 2 tBu; CH 2 -azetidine substituted with halo; -CH 2 -6-oxa-3-azabicyclo[3.1.1]heptan-3-yl; pyrazole substituted with C 1-5 alkyl; pyridyl; 3,6-dihydro-2H-pyridine substituted with -CO 2 tBu; imidazole; oxadiazolyl; and oxadiazole substituted with C 1-5 alkyl, cyclopropyl, pyridyl, or C 1-5 haloalkyl; R 4 is selected from the group consisting of: H, halo, and C 1-5 haloalkoxy; R 5 is selected from the group consisting of: H, halo, C 1-5 alkyl, C 1-5 haloalkyl, -CN, - CO 2 C 1-5 alkyl, -(C=O)NH-phenyl, -(C=O)pyrrolidine, and -(C=O)piperidine; and R 6 is selected from the group consisting of: H, halo, C 1-5 alkyl, -CH 2 CN, C 1-5 alkoxy, C 1-5 haloalkyl, and C 1-5 haloalkoxy; and wherein when R 6 is H and R 2 is C 1-5 alkoxy, R 3 is not C 1-5 alkoxy; and pharmaceutically acceptable salts, N-oxides, or solvates thereof; wherein 2-Oxo-6-(2-chlorophenyl)benzothiazoline is disclaimed. X is NH or S; R 1a and R 1b are independently selected from the group consisting of H, 3 H, halo, -CH 3, -CH 2 CH 3, -CF 3, -OCH 3, -OCF 3, and -CN; R 2 is selected from the group consisting of: halo; C 1-5a lkyl; C 1-5 alkenyl; C 1-5 haloalkyl; C 1-5 alkoxy; C 1-5 haloalkoxy; -(C=O)H; -CH 2 C(=O)NH(CH 3); -CO 2 C 1-5 alkyl; -CN; - CH 2 CN; -CH(CH 3)CN; -C(CH 3) 2 CN; -OCH 2 CN; phenyl; phenyl substituted with halo, C 1-5 alkoxy, or -CN; -O-phenyl; benzyl; benzyl substituted with halo; -O-benzyl; C 3-6 cycloalkyl; -OC 3-6 cycloalkyl; -O-thiazolyl; pyrimidinyl; pyridyl; pyridyl substituted with halo, C 1-5 alkoxy, or C 1-5 haloalkyl; -NH-CH 2 -furyl; -C 3-6 cycloalkyl substituted with CN; -CH 2 morpholine; CH 2 -N-methylpiperazine; pyrazolyl; pyrazole substituted with -CH 2 CH 2 OCH 3, or C 1-5 alkyl; isoxazole substituted with two C 1-5 alkyl; -O-CH 2 -C 3-6 cycloalkyl optionally substituted with halo; piperazine substituted with -CO 2 tBu; - O-azetidine substituted with -CO 2 tBu; and 8-quinolyl; R 3 is selected from the group consisting of: H; halo; C 1-5 alkyl; C 1-5 haloalkyl; C 1-5 alkoxy; C 1-5 haloalkoxy; -CN; -CH 2 CN; CO 2 C 1-5 alkyl; -N(CH 3) 2; -(C=O)N(C 1-5 alkyl) 2; - (C=O)NH-cyclopropyl; -(C=O)NH-phenyl; -(C=O)morpholine; -O-cyclopropyl; -O-CH 2 -cyclopropyl substituted with halo; -O-azetidinyl substituted with -CO 2 tBu; CH 2 -pyrrolidine; piperidine; piperidine substituted with -OCH 3; -CH 2 -piperidine; -CH 2 -piperidine substituted with -OH and halo; -CH 2 -morpholine; CH 2 -morpholine substituted with one or two C 1-5 alkyl or C 1-5 haloalkyl; CH 2 -thiomorpholine; CH 2 -piperazine substituted with -CO 2 tBu; CH 2 -azetidine substituted with halo; -CH 2 -6-oxa-3-azabicyclo[3.1.1]heptan-3-yl; pyrazole substituted with C 1-5 alkyl; pyridyl; 3,6-dihydro-2H-pyridine substituted with -CO 2 tBu; imidazole; oxadiazolyl; and oxadiazole substituted with C 1-5 alkyl, cyclopropyl, pyridyl, or C 1-5 haloalkyl; R 4 is selected from the group consisting of: H, halo, and C 1-5 haloalkoxy; R 5 is selected from the group consisting of: H, halo, C 1-5 alkyl, C 1-5 haloalkyl, -CN, - CO 2 C 1-5 alkyl, -(C=O)NH-phenyl, -(C=O)pyrrolidine, and -(C=O)piperidine; and R 6 is selected from the group consisting of: H, halo, C 1-5 alkyl, -CH 2 CN, C 1-5 alkoxy, C 1-5 haloalkyl, and C 1-5 haloalkoxy; and